Immunological Memory Transferred with CD4 T Cells Specific for Tuberculosis Antigens Ag85B-TB10.4: Persisting Antigen Enhances Protection
Open Access
- 14 December 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (12) , e8272
Abstract
High levels of death and morbidity worldwide caused by tuberculosis has stimulated efforts to develop a new vaccine to replace BCG. A number of Mycobacterium tuberculosis (Mtb)-specific antigens have been synthesised as recombinant subunit vaccines for clinical evaluation. Recently a fusion protein of TB antigen Ag85B combined with a second immunodominant TB antigen TB10.4 was emulsified with a novel non-phospholipid-based liposomal adjuvant to produce a new subunit vaccine, investigated here. Currently, there is no consensus as to whether or not long-term T cell memory depends on a source of persisting antigen. To explore this and questions regarding lifespan, phenotype and cytokine patterns of CD4 memory T cells, we developed an animal model in which vaccine-induced CD4 memory T cells could transfer immunity to irradiated recipients. The transfer of protective immunity using Ag85B-TB10.4-specific, CD45RBlow CD62Llow CD4 T cells was assessed in sub-lethally irradiated recipients following challenge with live BCG, used here as a surrogate for virulent Mtb. Donor T cells also carried an allotype marker allowing us to monitor numbers of antigen-specific, cytokine-producing CD4 T cells in recipients. The results showed that both Ag85B-TB10.4 and BCG vaccination induced immunity that could be transferred with a single injection of 3×106 CD4 T cells. Ten times fewer numbers of CD4 T cells (0.3×106) from donors immunised with Ag85B-TB10.4 vaccine alone, transferred equivalent protection. CD4 T cells from donors primed by BCG and boosted with the vaccine similarly transferred protective immunity. When BCG challenge was delayed for 1 or 2 months after transfer (a test of memory T cell survival) recipients remained protected. Importantly, recipients that contained persisting antigen, either live BCG or inert vaccine, showed significantly higher levels of protection (p<0.01). Overall the numbers of IFN-γ-producing CD4 T cells were poorly correlated with levels of protection. The Ag85B-TB10.4 vaccine, with or without BCG-priming, generated TB-specific CD4 T cells that transferred protective immunity in mice challenged with BCG. The level of protection was enhanced in recipients containing a residual source of specific antigen that could be either viable or inert.Keywords
This publication has 52 references indexed in Scilit:
- Tuberculosis vaccines — an updateNature Reviews Microbiology, 2007
- The success and failure of BCG — implications for a novel tuberculosis vaccineNature Reviews Microbiology, 2005
- New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical developmentVaccine, 2005
- Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humansNature Medicine, 2004
- Long-term Efficacy of BCG Vaccine in American Indians and Alaska NativesJAMA, 2004
- Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the esat-6 Gene FamilyInfection and Immunity, 2002
- Failure of theMycobacterium bovisBCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to TuberculosisInfection and Immunity, 2002
- Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.2001
- Comparative Evaluation of Low-Molecular-Mass Proteins fromMycobacterium tuberculosisIdentifies Members of the ESAT-6 Family as Immunodominant T-Cell AntigensInfection and Immunity, 2000
- The Efficacy of Bacillus Calmette-Guérin Vaccination of Newborns and Infants in the Prevention of Tuberculosis: Meta-Analyses of the Published LiteraturePediatrics, 1995